Comparing Vimseltinib and Pexidartinib and Measuring Functional Outcomes With PROMIS

The faculty start this episode by comparing vimseltinib with pexidartinib. The hosts note that patients that are doing well on pexidartinib need not be switched, and with the risk evaluation and mitigation strategy (REMS) program and monitoring, real-world experience was described as quite good, even though concern about hepatotoxicity was real. Practical differences noted include dosing schedule and dietary considerations. On functional assessment, the Patient-Reported Outcomes Measurement Information System (PROMIS) is favored as a joint-agnostic tool, including a computer-adaptive version that takes about 2 minutes. The faculty also stress that a patient’s answer to how they are doing often shows within seconds whether to stay the course or pivot, with PROMIS supplying quantitative support.